8-K filed Jul 29, 2026 at 07:20 ET
Anika Therapeutics reported a transformative Q2 2026 beat, with GAAP EPS of $0.24 (vs $0.03 consensus) and revenue of $32.6M (vs $29.2M consensus), driven by record Commercial Channel revenue of $13.9M (+17% YoY) and gross margin expansion to 65%. The company raised full-year 2026 guidance across all metrics, most notably lifting adjusted EBITDA margin guidance from 5%-10% to 13%-17%, signaling a structural profitability inflection. The bullish read is tempered by the removal of Hyalofast revenue from 2027 guidance due to FDA timing uncertainty, but the magnitude of the beat and guidance raise dominates the narrative for a $202M market cap stock.